Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Exploratory Clinical Study on the Neoadjuvant Treatment of Neuroendocrine Cervix Carcinoma With Camrelizumab Combined With Etoposide and Cisplatin

NCT05910177 is registered in ClinicalTrials.gov with Fujian Cancer Hospital as lead sponsor.

NCT NCT05910177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05910177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Exploratory Clinical Study on the Neoadjuvant Treatment of Neuroendocrine Cervix Carcinoma With Camrelizumab Combined With Etoposide and Cisplatin
Lead sponsor
Fujian Cancer Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
December 28, 2023
Completion date
August 31, 2026
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, cervix carcinoma